Value of antimicrobials in the prevention and treatment of tuberculosis in the United States

International Journal of Tuberculosis and Lung Disease

Volumn 6, Issue 4, 2002, Pages 275-288

  Javitz, Harold S ^a   Ward, M ^a  

^a SRI INTERNATIONAL   (United States)

Author keywords

Antimicrobials; Cost of illness; Cost savings; Cost benefit analysis; Medical economics; Modern history of medicine; Tuberculosis

Indexed keywords

ANTIINFECTIVE AGENT;

COST BENEFIT ANALYSIS; DRUG COST; ECONOMIC ASPECT; FINANCIAL MANAGEMENT; HEALTH CARE COST; HUMAN; INCIDENCE; INFECTION CONTROL; LIFE EXPECTANCY; MORTALITY; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; TREATMENT PLANNING; TUBERCULOSIS; UNITED STATES;

ANTIBIOTICS, ANTITUBERCULAR; COST OF ILLNESS; COST SAVINGS; COST-BENEFIT ANALYSIS; HUMANS; INCIDENCE; QUALITY OF LIFE; TIME FACTORS; TUBERCULOSIS; UNITED STATES;

EID: 0036201575     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Reported tuberculosis in the United States, 1997
2. Recent advances in epidemiological research in tuberculosis
3. Tuberculosis now and then: A personal perspective on the last 50 years
4. Occupationally acquired infections in health care workers
5. The role of BCG vaccine in the prevention and control of tuberculosis in the United States
6. Global epidemiology of tuberculosis
7. Tuberculosis: Commentary on a re-emergent killer
8. Mycobacterium tuberculosis
9. A century of treating tuberculosis
10. Rocherfeller University Workshop Report. Multiple-antibiotic-resistant pathogenic bacteria
11. Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis
12. Health-care expenditures for tuberculosis in the United States
13. The cost of caring for patients with tuberculosis: Planning for a disease on the rise
14. A cost-effectiveness analysis of directly observed therapy vs. self-administered therapy for treatment of tuberculosis
15. Social and economic impact of infectious diseases - United States
16. Liver injury during antituberculosis treatment: An 11-year study
17. Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients
18. A controlled trial of six months chemotherapy in pulmonary tuberculosis. First report: Results during chemotherapy
19. Hepatic complications of antituberculous therapy revisited
20. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers
21. Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons
22. Underutilization of isoniazid chemoprophylaxis in tuberculosis contacts 50 years of age and older. A prospective analysis
23. Isoniazid-related fatal hepatitis
24. Hepatotoxicity of antituberculosis therapy (refampicin, isoniazid, and pyrazinamide) or viral hepatitis
25. Hepatotoxicity associated with isoniazid preventive therapy: A 7-year survey from a public health tuberculosis clinic
26. The cost-effectiveness of preventing tuberculosis in physicians using tuberculin skin testing or a hypothetical vaccine
27. Epidemiology of drug resistance: Implications for a post-antimicrobial era
28. Pitfalls in the care of patients with tuberculosis: Common errors and their association with the acquisition of drug resistance
29. Effect of HIV infection and tuberculosis on hospitalizations and cost of care for young adults in the United States, 1985 to 1990
30. Research without billing data: Econometric estimation of patient-specific costs
31. State-imposed limits on Medicaid reimbursement for nursing facility care
32. Deaths: Final data for 1996
33. The value of reducing risks to death: A note on new evidence
34. The value of risks to life and health
35. Doubling the estimated value of life: The implications of new occupational fatality data
36. The quality-adjusted value of life
37. Estimating the dollar value of health outcomes from drug-abuse interventions
38. Regulations restricting the sale and distribution of cigarettes and smokeless tobacco products to protect children and adolescents
39. Pharmacoeconomic profile of taxanes in advanced ovarian cancer
40. An overview of cost-utility analysis of prostate cancer screening
41. Cost/benefit relations in heart transplantation
42. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases
43. Cost-effective strategies for the management of vascular disease
44. Health economic consequences of the pharmacological treatment of heart failure
45. Methods for quality adjustment of life years
46. A scale of valuations for status of illness: Is there a social consensus?
47. The global epidemic: The present epidemiology of tuberculosis
48. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country
49. The new tuberculosis
50. Multiple drug-resistant tuberculosis
51. Origin and spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family
52. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence
53. Tuberculosis symposium: Emerging problems and promise
54. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis
55. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin
56. Outcome of MDR-TB patients, 1983-1993: Prolonged survival with appropriate therapy
57. Multiple drug-resistant tuberculosis
58. Risk factors for the spread of antibiotic-resistant bacteria
59. New horizons in the treatment of tuberculosis
60. The BCG experience: Implications for future vaccines against tuberculosis
61. Six years' experience with the discontinuation of BCG vaccination
62. A cost-benefit analysis of BCG revaccination in the Czech Republic
63. Prospects for vaccines to protect against aids, tuberculosis, and malaria
64. Control of antimicrobial resistance in the health care system
65. Can antibiotic resistance be controlled?
66. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals - A challenge to hospital leadership
67. Noscomial infection caused by antibiotic resistant organisms in the intensive-care unit
68. Emerging infections: Getting ahead of the curve
69. Resistance to antimicrobial drugs - A worldwide calamity